Business Description
Avalo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US15671L1098
Total Employee Number:
33Description
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1654.03 | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 13.81 | |||||
Beneish M-Score | -3.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -97.9 | |||||
3-Year EBITDA Growth Rate | 82.2 | |||||
3-Year EPS without NRI Growth Rate | 82.9 | |||||
3-Year FCF Growth Rate | 82.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 17.86 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.99 | |||||
9-Day RSI | 55.51 | |||||
14-Day RSI | 54.84 | |||||
3-1 Month Momentum % | -1.92 | |||||
6-1 Month Momentum % | 37.65 | |||||
12-1 Month Momentum % | 116.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.31 | |||||
Quick Ratio | 19.31 | |||||
Cash Ratio | 18.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -680.1 | |||||
Shareholder Yield % | 0.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -154844.07 | |||||
Net Margin % | -170055.93 | |||||
EBITDA Margin % | -154659.32 | |||||
FCF Margin % | -117524 | |||||
OCF Margin % | -117524 | |||||
ROE % | -63.01 | |||||
ROA % | -52.32 | |||||
ROIC % | -316.78 | |||||
3-Year ROIIC % | 323.06 | |||||
ROC (Joel Greenblatt) % | -19429.6 | |||||
ROCE % | -50.99 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6533.33 | |||||
PB Ratio | 2.31 | |||||
Price-to-Tangible-Book | 2.37 | |||||
EV-to-EBIT | -7.13 | |||||
EV-to-Forward-EBIT | 29.17 | |||||
EV-to-EBITDA | -7.14 | |||||
EV-to-Revenue | 11035.83 | |||||
EV-to-Forward-Revenue | 1.94 | |||||
EV-to-FCF | -9.53 | |||||
Price-to-GF-Value | 98 | |||||
Price-to-Median-PS-Value | 555.33 | |||||
| Price-to-Net-Current-Asset-Value | 2.84 | |||||
| Price-to-Net-Cash | 2.9 | |||||
Earnings Yield (Greenblatt) % | -14.03 | |||||
FCF Yield % | -6.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avalo Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.05 | ||
| EPS (TTM) (€) | -3.75 | ||
| Beta | 4.0668 | ||
| 3-Year Sharpe Ratio | 0.46 | ||
| 3-Year Sortino Ratio | 2.02 | ||
| Volatility % | 76.17 | ||
| 14-Day RSI | 54.84 | ||
| 14-Day ATR (€) | 0.451998 | ||
| 20-Day SMA (€) | 16.28 | ||
| 12-1 Month Momentum % | 116.95 | ||
| 52-Week Range (€) | 7.44 - 19.32 | ||
| Shares Outstanding (Mil) | 53.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avalo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avalo Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 82 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 15.92 (+0.00%) | ||
| BTIG Biotechnology Conference | 2026-07-29 10:30 | 16.94 (+0.00%) | ||
| General meeting for 2026 | 2026-06-02 08:30 | 13.50 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 17.00 (+0.00%) | ||
| Annual report for 2025 | 2026-03-23 | 11.76 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 11.76 (+0.00%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 16:20 | 14.54 (+0.00%) | ||
| TD Cowen Annual Healthcare Conference | 2026-03-03 09:50 | 14.52 (+0.00%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 10:00 | 12.38 (+0.00%) |
Show
Entries
Avalo Therapeutics Inc Frequently Asked Questions
What is Avalo Therapeutics Inc(FRA:C6K0)'s stock price today?
The current price of FRA:C6K0 is €16.66. The 52 week high of FRA:C6K0 is €19.32 and 52 week low is €7.44.
When is next earnings date of Avalo Therapeutics Inc(FRA:C6K0)?
The next earnings date of Avalo Therapeutics Inc(FRA:C6K0) is 2026-11-06 Est..
Does Avalo Therapeutics Inc(FRA:C6K0) pay dividends? If so, how much?
Avalo Therapeutics Inc(FRA:C6K0) does not pay dividend.
Press Release
Articles on Avalo Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers